Reply to the letter to the editor 'The ESMO magnitude of clinical benefit scaling tool: From theory to practice' by Hartmann and the letter 'Comment on ESMO magnitude of clinical benefit scale' by Muhonen et al.

Annals of Oncology

Volumn 27, Issue 1, 2016, Pages 203-205

  Cherny, N I ^a   Sullivan, R ^b   Dafni, U ^c   Kerst, J M ^d   Sobrero, A ^e   Zielinski, C ^f   De Vries, E G E ^g   Piccart, M J ^h  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF ATHENS   (Greece)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e UNIVERSITY OF GENOA   (Italy)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTICAL RESEARCH; ATTITUDE TO HEALTH; BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL BENEFIT SCALING TOOL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONFIDENCE INTERVAL; HEALTH CARE POLICY; HEALTH HAZARD; HEALTH SERVICE; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; ISRAEL; LETTER; ONCOLOGY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; STATISTICAL ANALYSIS; NEOPLASMS; OUTCOME ASSESSMENT; PROCEDURES;

HUMANS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84960090868     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv502     Document Type: Letter

References (6)

1. Muhonen T, Joensuu H, Pfeiffer P. Comment on ESMO Magnitude of Clinical Benefit Scale. Ann Oncol 2015 Sep 27 [epub ahead of print], doi:10.1093/annonc/mdv384.
2. Hartmann M. The ESMO magnitude of clinical benefit scaling tool: from theory to practice. Ann Oncol 2015 Sep 23 [epub ahead of print], doi:10.1093/annonc/mdv367.
3. European network for Health Technology Assessment. Guideline: Endpoints used for relative effectiveness assessment of pharmaceuticals: Clinical endpoints In. 2013; http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Clinical%20endpoints. pdf (28 October 2015, date last accessed).
4. European network for Health Technology Assessment. Guideline: Endpoints used in relative effectiveness assessment of pharmaceuticals: Surrogate Endpoints In. 2013; http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Surrogate%20Endpoints.pdf (28 October 2015, date last accessed).
5. European network for Health Technology Assessment. Guideline: Levels of evidence: Applicability of evidence in the context of a relative effectiveness assessment of pharmaceuticals: health-related quality of life and utility measures In. 2013; http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Health-related %20quality%20of%20life.pdf (28 October 2015, date last accessed).
6. European network for Health Technology Assessment. Guideline: Levels of evidence: Applicability of evidence in the context of a relative effectiveness assessment of pharmaceuticals In. 2013; http://www.eunethta.eu/sites/5026. fedimbo.belgium.be/files/Applicability.pdf (28 October 2015, date last accessed).